| 摘要 |
<p>Cancerous metastasis inhibitors for oral administration which contain as the active ingredient one or more substances selected from the group consisting of iron-free saturated lactoferrin, hydrolyzates of lactoferrins, pharmaceutically acceptable derivatives of these hydrolyzates, pharmaceutically acceptable salts of these hydrolyzates, peptides originating in the hydrolyzates of lactoferrins, pharmaceutically acceptable derivatives of these peptides, and pharmaceutically acceptable salts of these peptides. These cancerous metastasis inhibitors are reduced in side effects and can be orally administered over a long period of time, thus exerting inhibitory effects on cancerous metastasis.</p> |
